Comparison · NCT01902290-sae
Brodalumab 210 mg vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Brodalumab 210 mg vs Placebo: serious adverse events. Trial comparisons, record NCT01902290-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01902290-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0337 | 0.0164 | 0.0678 | wilson | |
| Risk in group 2 | 0.0386 | 0.0197 | 0.0744 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00499 | -0.0447 | 0.0341 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.871 | 0.322 | 2.36 | log | |
| Odds ratio, group 1 over group 2 | 0.866 | 0.308 | 2.43 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Brodalumab 210 mg than on Placebo | 200 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Brodalumab 210 mg | Participants received brodalumab 210 mg administered by subcutaneous injection on day 1 and weeks 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 22. | 7 | 208 | EG001 |
| Group 2 | Placebo | Participants received placebo subcutaneous injections on day 1 and weeks 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 22. | 8 | 207 | EG000 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- From first dose of study drug until the end of study, week 28.
Source ClinicalTrials.gov
Trial
- Title
- Study of Efficacy and Safety of Brodalumab Compared With Placebo in Adults With Inadequately Controlled Asthma With High Bronchodilator Reversibility
- NCT number
- NCT01902290
- Phases
- PHASE2
- Conditions
- Asthma
- Interventions
- Placebo, Brodalumab
- Lead sponsor
- Amgen
- Results first posted
- 2022-02-28
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01902290?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01902290-sae